TransMedics is reaffirmed as a buy, with significant upside potential based on improved margins and slower share dilution. I estimate 2028 revenue at $1.35 billion, driven by achieving 10k transplants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback